Using the latest genomic research tools, we are developing highly targeted therapies that address the underlying genetic drivers of Amyotrophic Lateral Sclerosis (ALS).
At Black Swan Biotech we combine next generation genomics research with precision oligonucleotide therapeutics to target the genetic drivers of ALS and other CNS diseases — developing treatments designed to reach the drivers of disease in the brain and spinal cord.
ALS is not one disease with one trajectory. Every person living with ALS can experience a different course of disease and may respond differently to treatment. Yet the field still lacks the tools to fully understand the biological mechanisms driving these differences.
NeuroPMO™ combines advanced PMO chemistry with precision medicine principles to accelerate the development of targeted therapies for people living with ALS and other CNS diseases.
The evidence is clear: therapies supported by human genetic evidence are 2.6 to 5 times more likely to succeed in the clinic than conventional drug development approaches. By starting with human biology, precision medicine helps identify the patients most likely to benefit from a targeted therapy: improving clinical outcomes, reducing trial failure, and delivering more efficient healthcare.
One Treatment Fits All
And Precision Diagnosis
Our mission is patient centric; we work with researchers and clinicians to ensure that we maximise our potential to uncover deeper biological insights, identify meaningful patient subgroups, and accelerate the development of targeted PMO-based therapies for people living with ALS and other CNS
diseases.
Whether you're interested in research collaboration, strategic partnerships, investment opportunities, or learning more about our technology, we'd love to hear from you.
